Roche reports another phase 3 multiple sclerosis win, but deaths add to safety questions
Roche reports another phase 3 multiple sclerosis win, but deaths add to safety questions
Roche reports another phase 3 multiple sclerosis win, but deaths add to safety questions
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.